RECLOVAC 90 FILM COATED TABLETS 90MG [SIN17266P]
Active ingredients: RECLOVAC 90 FILM COATED TABLETS 90MG
Last updated 24 April 2026
Product Info
RECLOVAC 90 FILM COATED TABLETS 90MG
[SIN17266P]
Product information
Active Ingredient and Strength | TICAGRELOR - 90 MG |
Dosage Form | TABLET, FILM COATED |
Manufacturer and Country | DR. REDDY'S LABORATORIES LIMITED - INDIA |
Registration Number | SIN17266P |
Licence Holder | EURO ASIA MEDICO PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | B01AC24 |
Prescription-only Medicines with Exemptions for Supply without Prescription | NA |
Indication
Therapeutic indications
Ticagrelor, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of thrombotic events (cardiovascular death, myocardial infarction and stroke) in patients with Acute Coronary Syndromes (ACS) (unstable angina, non-ST elevation Myocardial Infarction [NSTEMI], or ST elevation Myocardial Infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).
Dosing
Posology and method of administration
In patients with Acute Coronary Syndromes, ticagrelor treatment should be initiated with a single 180 mg loading dose (two tablets of 90 mg) and then continued at 90 mg twice daily. Treatment is recommended for at least 12 months unless discontinuation of TICAGRELOR is clinically indicated (see section Pharmacodynamic properties). After one year, patients with MI initiated on 90 mg may continue treatment with 60 mg without interruption if they have a high risk of an atherothrombotic event.
Patients taking ticagrelor should also take a daily low maintenance dose of acetylsalicylic acid (ASA) of 75–150 mg, unless specifically contraindicated. An initial loading dose of ASA, is recommended for patients with ACS (see section Pharmacodynamics properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Missed dose
Lapses in therapy should be avoided. A patient who misses a dose of ticagrelor should take their next dose at its scheduled time.
Switching
Physicians who desire to switch patients, with a prior ACS event to ticagrelor, should administer the first 90 mg dose of ticagrelor 24 hours following the last dose of other antiplatelet medication (see section Pharmacodynamic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Premature discontinuation
Premature discontinuation with any antiplatelet therapy, including TICAGRELOR, could result in an increased risk of cardiovascular (CV) death, myocardial infarction (MI), or stroke due to the patient’s underlying disease (see section Special warnings and special precautions for use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Administration
For oral use. Ticagrelor can be taken with or without food. For patients who are unable to swallow the tablet(s) whole, ticagrelor tablets can be crushed to a fine powder and mixed in half a glass of water and drunk immediately. The glass should be rinsed with a further half glass of water and the contents drunk. The mixture can also be administered via a nasogastric tube (CH8 or greater). It is important to flush the nasogastric tube through with water after administration of the mixture.
Special Populations
Paediatric patients:
Safety and efficacy in children below the age of 18 have not been established (see section Pharmacodynamic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Elderly patients:
No dose adjustment is required.
Patients with renal impairment:
No dose adjustment is necessary for patients with renal impairment (see section Pharmacokinetic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Patients with hepatic impairment:
No dose adjustment is necessary for patients with mild hepatic impairment. Ticagrelor has not been studied in patients with severe hepatic impairment and there is limited information on treatment of patients with moderate hepatic impairment (see section Contraindications, Special warnings and special precautions for use, and Pharmacokinetic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Contraindications
Contraindications
Hypersensitivity to ticagrelor or any of the excipients (see section Undesirable effects – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Active pathological bleeding.
History of intracranial haemorrhage (see section Undesirable effects – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Severe hepatic impairment (see section Posology and method of administration, Special warnings and special precautions for use and Pharmacokinetic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Co-administration of ticagrelor with strong CYP3A4 inhibitors (e.g. ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir) is contraindicated, as coadministration may lead to a substantial increase in exposure to ticagrelor (see section Special warnings and special precautions for use and Interaction with other medicinal products and other forms of interaction – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).